Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial.
Luís PuigAndrey L BakulevMuza M KokhanAlexey V SamtsovVladislav R KhairutdinovMaria A MorozovaNikita A ZolkinIvan V KuryshevAlexey N PetrovAntonina V ArtemevaArina V Zinkina-OrikhanPublished in: Dermatology and therapy (2021)
The trial is registered at the US National Institutes of Health (ClinicalTrials.gov; NCT03390101).
Keyphrases
- placebo controlled
- monoclonal antibody
- double blind
- phase iii
- clinical trial
- phase ii
- study protocol
- healthcare
- public health
- phase ii study
- coronary artery disease
- mental health
- quality improvement
- open label
- health information
- early onset
- randomized controlled trial
- human health
- health promotion
- atopic dermatitis
- risk assessment
- squamous cell carcinoma